Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. World journal of urology Zargar-Shoshtari, K., Zargar, H., Dinney, C. P., Ercole, C. E., Sharma, P., Kovac, E., Grivas, P. D., Stephenson, A. J., Shah, J. B., Black, P. C., Spiess, P. E. 2016; 34 (5): 695-701

Abstract

Several disease characteristics have been identified as potential predictors for pathological node involvement (pN+) following radical cystectomy (RC). However, these have not been assessed in patients treated with neoadjuvant chemotherapy (NAC). We endeavored to assess factors predicting adverse pathology in clinically node-negative patients treated with NAC and RC.Patients from four North American institutions with cT2-4aN0M0 UC who received three or four cycles of NAC followed by RC were selected. Logistic regression was used to predict pN+,

View details for DOI 10.1007/s00345-015-1667-4

View details for PubMedID 26286880